# A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

> **NCT05215067** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 44 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AK104
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05215067
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215067, "A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05215067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*